NCCN Guidelines® Insights - Bladder Cancer, Version 2.2016
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.
This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Bladder Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Bladder Cancer
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Peter E. Clark, MD, Panel Chair, has disclosed that he is a scientific advisor for Genentech, Inc.
Philippe E. Spiess, MD, MS, has disclosed that he receives consulting fees and/or honoraria from Janssen Pharmaceutica Products, LP, and Prometheus Laboratories Inc.
Rick Bangs, MBA, Panel Member, has disclosed that he has no relevant financial relationships.
Stephen A. Boorjian, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Thomas W. Flaig, MD, Panel Member, has disclosed that he is the founder of Aurora Oncology, and that he receives honoraria from GTx, Inc. and BN ImmunoTherapeutics, Inc. He also receives grant/research support from from GTx, Inc.; BN ImmunoTherapeutics, Inc.; Novartis Pharmaceuticals Corporation; Dendreon Corporation; Janssen Pharmaceutica Products, LP/Cougar Biotechnology; Pfizer Inc.; Medivation, Inc.; sanofi-aventis; Bristol-Myers Squibb Company; Roche/Genentech, Inc.; Exelixis Inc.; Aragon Pharmaceuticals Inc.; SOTIO, LLC; Tokai Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; and Astellas US LLC.
Noah Hahn, MD, Panel Member, has disclosed that he receives consulting fees from Genentech, Inc.; AstraZeneca Pharmaceuticals /MedImmune, LLC; Inovio Pharmaceuticals, Inc.; Principia Biopharma Inc.; and Merck & Co., Inc. He also receives research support from Novartis Pharmaceuticals Corporation; Heat Biologics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals/ MedImmune, LLC; Merck & Co., Inc.; Acerta Pharma; and Principia Biopharma Inc.
A. Karim Kader, MD, PhD, Panel Member, has disclosed that he is a consultant for Pellficure Pharmaceuticals, Inc., and is a founder, board member, and officer for SNP Bio, Inc.
Joshua J. Meeks, MD, PhD, Panel Member, has disclosed that he has no relevant financial relationships.
Lance C. Pagliaro, MD, Panel Member, has disclosed that he receives honoraria from sanofi-aventis and Novartis Pharmaceuticals Corporation.
Elizabeth R. Plimack, MD, MS, Panel Member, has disclosed that she is a scientific advisor for Acceleron Pharma, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche, and SynerGene Therapeutics; and receives grant/research support from Acceleron Pharma, Inc., AstraZeneca Pharmaceuticals LP, AVEO Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Dendreon Corporation, Glaxo SmithKline, Eli Lilly and Company, Merck & Co., Inc., Peloton Therapeutics, Inc., and Pfizer Inc.
Wade J. Sexton, MD, Panel Member, has disclosed that he is on the advisory board for Altor BioScience Corporation.
Arlene O. Siefker-Radtke, MD, Panel Member, has disclosed that she is a member of the advisory board for Janssen Pharmaceuticals, Inc.; Eisai Inc.; Genentech, Inc.; and AstraZeneca Pharmaceuticals LP.
Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.
Courtney Smith, PhD, MT(ASCP), Oncology Scientist/Medical Writer, NCCN, has disclosed that she receives equity interest/stock options from Johnson & Johnson and Opko Health.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-16-010-H01-P
All clinicians completing this activity will be issued a certificate of participation.
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation